Research Article
Obstacle Avoidance amongst Parkinson Disease Patients Is Challenged in a Threatening Context
Table 1
Clinical information of the Parkinson disease patient group.
| Patient | Age (yr) | Disease duration | Sex | UPDRS-III* | Symptoms (OFF) | Medication | | | | | ON | OFF | Bradykinesia | Action Tremor | Resting Tremor |
| 1 | 80 | 15 | M | 28 | 45 | Y | Y | Y | Levodopa Levodopa (sustained release) | 2 | 69 | 4 | M | 18 | 40 | Y | Y | Y | Levodopa | 3 | 76 | 8 | M | 6 | 24 | Y | Y | N | Levodopa Levodopa (sustained release) Pramipexole | 4 | 75 | 1 | M | 6 | 17 | Y | N | Y | Levodopa | 5 | 81 | 7 | M | 16 | 33 | Y | Y | Y | Levodopa Pramipexole | 6 | 54 | 10 | F | 5 | 14 | Y | N | Y | Levodopa Pergolide mesylate Amantadine | 7 | 54 | 22 | F | 21 | 43 | Y | Y | Y | Levodopa Pramipexole | 8 | 80 | 2 | F | 38 | 54 | Y | Y | Y | Levodopa Amantadine | 9 | 63 | 2 | F | 22 | 58 | Y | Y | Y | Levodopa | 10 | 65 | 11 | F | 21 | 34 | Y | Y | N | Levodopa Pramipexole | Mean (SD) | 69.7 (10.3) | 8.2 (6.6) | | 18.1 (10.5) | 36.2 (14.7) | | | | |
|
|
The Unified Parkinson Disease Rating Scale-III (motor component—questions 18–31), with higher scores indicative of greater motor deficit.
|